Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth.

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

The domestic equity benchmarks ended lower on Friday, snapping a two-day winning streak. Selling pressure from foreign institutional investors (FIIs) and a strengthening US dollar weighed on investor ...

IST, the barometer index, the S&P BSE Sensex, shed 45.42 points or 0.07% to 76,474.96. The Nifty 50 index fell 20.60 points or 0.09% to 23,184.75.

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Motilal Oswal recommended Neutral rating on Dr Reddys Labs with a target price of Rs 1330 in its research report dated ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.